Cipla Expands Distribution of Eli Lilly's Tirzepatide in India Under Yurpeak Brand

Eli Lilly and Cipla have entered into an agreement to distribute and promote the weight-loss and type 2 diabetes drug tirzepatide in India under a second brand name, Yurpeak. Cipla will handle marketing and distribution while Lilly will manufacture the drug, which will be priced the same as Lilly's existing brand Mounjaro. Tirzepatide, a dual agonist of GIP and GLP-1 receptors, is used as an adjunct for type 2 diabetes and obesity management and has shown strong market performance, with Mounjaro becoming the second most valuable drug in India shortly after launch. This partnership aims to expand access to this innovative therapy beyond Tier-1 cities, addressing the growing burden of diabetes and obesity in India. Both companies emphasize their commitment to improving patient care and offering innovative and accessible treatment options. The introduction of Yurpeak marks Cipla's entry into obesity care and strengthens the collaboration between the two companies, which previously partnered on insulin products.